Unknown

Dataset Information

0

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.


ABSTRACT: Trials focusing on unresectable multifocal glioblastoma are needed because of the extremely poor prognosis and challenges in receiving standard therapy, such as concurrent radiation and chemotherapy.Developing a strategy to chemically debulk tumors before radiation and/or surgery is warranted.Extent of resection remains a key prognostic factor in glioblastoma (GBM), with gross total resection providing a better prognosis than biopsy or subtotal resection. We conducted a phase II trial of upfront therapy with bevacizumab (BV), irinotecan (CPT-11), and temozolomide (TMZ) prior to chemoradiation in patients with unresectable, subtotally resected, and/or multifocal GBM.Patients received up to 4 cycles of TMZ at 200 mg/m(2) per day on days 1-5 (standard dosing) and BV at 10 mg/kg every 2 weeks on a 28-day cycle. CPT-11 was given every 2 weeks on a 28-day cycle at 125 mg/m(2) or 340 mg/m(2) depending on antiepileptic drugs. Magnetic resonance imaging of the brain was done every 4 weeks, and treatment continued as long as there was no tumor progression or unmanageable toxicity. The primary endpoint was tumor response rate, with a goal of 26% or greater.Forty-one patients were enrolled from December 2009 to November 2010. Radiographic responses were as follows: 9 patients (22.0%) had partial response, 25 (61.0%) had stable disease, and 2 (4.9%) had progression; 5 patients were not assessed. Cumulative response rate was 22%. Median overall survival was 12 months (95% confidence interval: 7.2-13.5 months).Upfront treatment with BV, TMZ, and CPT-11 is tolerable and can lead to radiographic response in unresectable and/or subtotally resected GBM.

SUBMITTER: Peters KB 

PROVIDER: S-EPMC4492239 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.

Peters Katherine B KB   Lou Emil E   Desjardins Annick A   Reardon David A DA   Lipp Eric S ES   Miller Elizabeth E   Herndon James E JE   McSherry Frances F   Friedman Henry S HS   Vredenburgh James J JJ  

The oncologist 20150529 7


<h4>Lessons learned</h4>Trials focusing on unresectable multifocal glioblastoma are needed because of the extremely poor prognosis and challenges in receiving standard therapy, such as concurrent radiation and chemotherapy.Developing a strategy to chemically debulk tumors before radiation and/or surgery is warranted.<h4>Background</h4>Extent of resection remains a key prognostic factor in glioblastoma (GBM), with gross total resection providing a better prognosis than biopsy or subtotal resectio  ...[more]

Similar Datasets

| S-EPMC3639657 | biostudies-literature
| S-EPMC3616617 | biostudies-literature
| S-EPMC5555116 | biostudies-literature
| S-EPMC4523080 | biostudies-literature
| S-EPMC6007398 | biostudies-literature
| S-EPMC5947454 | biostudies-literature
| S-EPMC6792497 | biostudies-literature
| S-EPMC7034757 | biostudies-literature
2024-08-26 | GSE275628 | GEO
| S-EPMC3158844 | biostudies-literature